Find a Clinical Trial

Showing 1 - 10 out of 13

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

Ischemic stroke, Transient ischemic attack

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Evaluation of BE1116 (4F-PCC) in patients with traumatic injury and confirmed or suspected acute major bleeding to improve survival

A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled,Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra^® / Beriplex^®]) to Improve Survival in Patients with Traumatic Injury and Confirmed or Suspected Acute Major Bleeding Predicted to Receive a Large Volume Blood Product Transfusion

Trauma

All genders

15+

Recruiting now

Department of Surgery, Division of Trauma

Tufts Medical Center

Learn more

SUMMIT MAX

A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint^® Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients

Stroke

All genders

18-85

Recruiting now

Department of Neurosurgery

Tufts Medical Center

Learn more

AbbVie EAISE

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Stroke

All genders

30-80

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

PFO-PAS

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Stroke

All genders

18-60

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

ASPIRE

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Intracerebral hemorrhage

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

AbCLO Open Abdomen Study

Assessment of a non-invasive device in the management of Open Abdomen – Pilot Study

Surgery, Trauma

All genders

18-99

Recruiting now

Department of Surgery

Tufts Medical Center

Learn more

ARCADIA

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Stroke

All genders

45+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

NRAD

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.

Alzheimer's disease, Mild cognitive impairment

All genders

55-89

Recruiting now

Department of Psychiatry

Tufts Medical Center

Learn more

THC-AD

Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (AD) (THC-AD)

Alzheimer's disease, Psychiatric disorders

All genders

60-95

Recruiting now

Department of Psychiatry

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint^® Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Assessment of a non-invasive device in the management of Open Abdomen – Pilot Study

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.

Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (AD) (THC-AD)